Royalty Pharma plc Stock News

NEW YORK, June 08, 2022 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it is scheduled to present at the Goldman Sachs 43rd Annual Global Healthcare Conference on June 14,

Royalty Pharma lets you diversify within the healthcare sector. A bear market is actually conducive to its business model.

NEW YORK, May 23, 2022 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it is scheduled to present at the UBS Global Healthcare Conference 2022 on May 24, 2022 at 1:15 p.m. E

The Oracle of Omaha was very active in the markets.

Royalty Pharma plc (NASDAQ:RPRX ) Q1 2022 Earnings Conference Call May 5, 2022 8:00 AM ET Company Participants George Grofik - Senior Vice President, Head-Investor Relations & Communications Terry Coy

Royalty Pharma (RPRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

NEW YORK, April 13, 2022 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it will report its first quarter 2022 financial results on Thursday, May 5, 2022 before the U.S. fin

NEW YORK, March 03, 2022 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it is scheduled to participate in a fireside chat at Cowen’s 42 nd Annual Health Care Conference on March 8, 2022 at 11:10 a.m. ET.

NEW YORK, March 03, 2022 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it is scheduled to participate in a fireside chat at Cowen's 42nd Annual Health Care Conference on M

If history is any guide, there may be good fortune ahead for shares of Royalty Pharma (NASDAQ: RPRX ). A so-called "golden cross" has formed on its chart and, not surprisingly, this could be bullish for the stock. What To Know: Many traders use moving average crossover systems to make their decisions. When a shorter-term average price crosses above a longer-term average price, it could mean the stock is trending higher. If the short-term average price crosses … Full story available on Benzinga.com

RPRX earnings call for the period ending December 31, 2021.

Royalty Pharma press release (RPRX): Q4 consolidated net income of $54M.Revenue of $576M (+0.7% Y/Y) beats by $32.63M.Full Year 2022 guidance: Adjusted Cash Receipts of $2,225 to…

NEW YORK, Feb. 15, 2022 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today reported financial results for the fourth quarter and full year of 2021 and introduced 2022 Adjusted Cash Receipts ( 1) (a non-GAAP financial measure) guidance.

Royalty Pharma's (RPRX) CEO Pablo Legorreta on Q4 2021 Results - Earnings Call Transcript